Exact Therapeutics AS

Exact Therapeutics AS Equity

The The Equity of Exact Therapeutics AS (EXTX.OL) as of Oct 11, 2026 is 30.71 M NOK. In the previous year, The Equity was 115.55 M NOK — a change of -73.42% (lower).

Equity

30.71 MNOK

YoY

-73.42%

Last updated:

In 2025, Exact Therapeutics AS's equity was 30.71 M NOK, a -73.42% increase from the 115.55 M NOK equity in the previous year.

The Exact Therapeutics AS Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
57.06 M NOK
Jan 1, 2019
42.24 M NOK
Jan 1, 2020
159.65 M NOK
Jan 1, 2021
105.74 M NOK
Jan 1, 2022
65.11 M NOK
Jan 1, 2023
45.10 M NOK
Jan 1, 2024
115.55 M NOK
Jan 1, 2025
30.71 M NOK
The Exact Therapeutics AS Equity history
YEAREquityYoY
30.71 MNOK-73.42%
115.55 MNOK+156.20%
45.10 MNOK-30.73%
65.11 MNOK-38.43%
105.74 MNOK-33.77%
159.65 MNOK+278.00%
42.24 MNOK-25.98%
57.06 MNOK+583.67%
8.35 MNOK—
Access this data via the Eulerpool API
Get Free API Key

Exact Therapeutics AS Stock analysis

What does Exact Therapeutics AS do? Exact Therapeutics AS is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Exact Therapeutics AS's Equity

Exact Therapeutics AS's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Exact Therapeutics AS's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Exact Therapeutics AS's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Exact Therapeutics AS's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Exact Therapeutics AS’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Exact Therapeutics AS stock

The Equity of Exact Therapeutics AS is 30.71 M NOK in 2025.

The Equity of Exact Therapeutics AS changed from 115.55 M NOK to 30.71 M NOK, representing a -73.42% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Exact Therapeutics AS since 2006 – with annual values, charts, and detailed analysis.

The Equity's NOK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Exact Therapeutics AS historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — Exact Therapeutics AS

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Exact Therapeutics AS